In spite that drug-eluting stents (DES), particularly newer generations, are the gold standard in treating significant coronary artery lesions, there is at least 2-4% risk of target lesion failure (TLF) per year, in the form of in-stent restenosis (ISR). The risk of In-stent restenosis (ISR) is invariably higher when you are obliged to use smaller […]